Thomas Leoo appointed new VP/Medical Director at Orexo AB

14 April 2005 · Pressrelease · Regulatory
Dr. Thomas Leoo has been appointed new Vice President & Medical Director at Orexo AB, based in Uppsala, Sweden. With his broad experience from clinical development, he adds important expertise to the company’s continued expansion.

Orexo is a product focused drug-delivery company that uses well-documented substances to develop new, innovative and patented pharmaceuticals. The company is currently in an expansive phase, in which a number of new products are being prepared for clinical testing and the development of existing product candidates in Phase I –II are being accelerated. “Thomas has broad experience of clinical development and dealing with pharmacovigilance, from among other positions as Medical Director at Sanofi-Aventis. We are confident that this experience will be a valuable addition as we embark on broadening of the product portfolio and in conjunction of Orexo’s product candidates reaching the clinical development phase,” says Zsolt Lavotha, President and CEO of Orexo.’ Dr. Thomas Leoo assumes his position on May 2 and succeeds Anders Pettersson as VP & Medical Director. Dr. Pettersson will be responsible full time for identifying and evaluating the company’s future product candidates. “As one of Orexo’s founders, Anders Pettersson has been involved in building the company to its current level during which he also carried the responsibility as Medical Director. In this capacity he also played an important role during the build-up of the company’s existing portfolio of product candidates,” says Zsolt Lavotha. Orexo’s product portfolio currently comprises one commercialized product, a number of product candidates in late clinical development phases and some well-advanced formulations projects. The common denominator for Orexo’s products is that they fulfill obvious needs on the market and have significant medical and commercial potential, can be patented and developed rapidly, with lower development risk and lower costs than traditional pharmaceutical development. For further information, please contact: Zsolt Lavotha, President & CEO, Orexo AB +46 (0)18 780 88 00. E-mail: zsolt.lavotha@orexo.se Johan Tamsen, Corporate Communications +46 (0)733 25 40 10, E-mail: johan.tamsen@orexo.se